寡腺苷酸合成酶基因家族的功能及其在肿瘤发生发展中作用的研究进展

doi:10.13481/j.1671-587X.20260534

Abstract

Abstract:

The oligoadenylate synthetase （OAS） family comprises interferon（IFN）-inducible antiviral proteins that are widely involved in biological processes including viral recognition， 2'-5'-linked oligoadenylate polymers（2-5A） synthesis， ribonuclease L （RNase L） activation， and cellular apoptosis. In recent years， their roles in oncology have attracted increasing attention. OAS family members exhibit aberrant expression in various solid tumors and hematological malignancies， participating in the regulation of tumorigenesis， tumor progression， immune evasion， and therapeutic resistance， thereby holding significant research value and clinical translational potential. In solid tumors， elevated expression of OAS1， OAS2， OAS3， and OAS like protein（OASL） is closely associated with poor prognosis， immune infiltration characteristics， and chemoresistance in cancer patients. Several members have been incorporated into prognostic prediction models across multiple studies， suggesting their potential utility as prognostic biomarkers and therapeutic targets. In hematological malignancies， OAS family members also participate in immune modulation and drug sensitivity regulation. This review systematically summarizes the structure and function of the OAS gene family， with a focus on the expression profiles， mechanistic roles， and clinical significance of OAS1， OAS2， OAS3， and OASL in different tumor types. Furthermore， we discuss their application prospects as diagnostic and therapeutic targets， along with the limitations of current research， aiming to provide a reference for subsequent basic and translational investigations.

Key words: OAS gene family, Tumor, Gene function, Immune regulation, Biomarkers

CLC Number:

R730.2

Xi ZHANG,Chunhui YANG,Li ZHAI,Jingjing CHEN,Yu ZHANG,Na MA. Research progress on functions of oligoadenylate synthetase gene family and their roles in occurrence and development of tumor[J].Journal of Jilin University(Medicine Edition), 2026, 52(5): 1520-1528.

References 69

[1]	YADAV M， SHARMA A， PATNE K， et al. AXL signaling in cancer： from molecular insights to targeted therapies［J］. Signal Transduct Target Ther， 2025， 10（1）： 37.
[2]	LOHÖFENER J， STEINKE N， KAY-FEDOROV P， et al. The activation mechanism of 2'-5'-oligoadenylate synthetase gives new insights into OAS/cGAS triggers of innate immunity［J］. Structure， 2015， 23（5）： 851-862.
[3]	LIN R J， YU H P， CHANG B L， et al. Distinct antiviral roles for human 2'，5'-oligoadenylate synthetase family members against dengue virus infection［J］. J Immunol， 2009， 183（12）： 8035-8043.
[4]	HARTMANN R， JUSTESEN J， SARKAR S， et al. Crystal structure of the 2'-specific and double-stranded RNA-activated interferon-induced antiviral protein 2'-5'-oligoadenylate synthetase［J］. Mol Cell， 2003， 12（5）： 1173-1185.
[5]	PADARIYA M， SZNARKOWSKA A， KOTE S， et al. Functional interfaces， biological pathways， and regulations of interferon-related DNA damage resistance signature （IRDS） genes［J］. Biomolecules， 2021， 11（5）： 622.
[6]	KERR I M， BROWN R E. pppA2'p5'A2'p5'A： an inhibitor of protein synthesis synthesized with an enzyme fraction from interferon-treated cells［J］. Proc Natl Acad Sci USA， 1978， 75（1）： 256-260.
[7]	GONZALEZ K J， MONCADA-GIRALDO D M， GUTIERREZ J B. In silico identification of potential inhibitors against human 2'-5'-oligoadenylate synthetase （OAS） proteins［J］. Comput Biol Chem， 2020， 85： 107211.
[8]	DI H， ELBAHESH H， BRINTON M A. Characteristics of human OAS1 isoform proteins［J］. Viruses， 2020， 12（2）： 152.
[9]	KAKUTA S， SHIBATA S， IWAKURA Y. Genomic structure of the mouse 2'， 5'-oligoadenylate synthetase gene family［J］. J Interf Cytokine Res， 2002， 22（9）： 981-993.
[10]	GOKUL A， ARUMUGAM T， RAMSURAN V. Genetic ethnic differences in human 2'-5'-oligoadenylate synthetase and disease associations： a systematic review［J］. Genes， 2023， 14（2）： 527.
[11]	DONOVAN J， DUFNER M， KORENNYKH A. Structural basis for cytosolic double-stranded RNA surveillance by human oligoadenylate synthetase 1［J］. Proc Natl Acad Sci USA， 2013， 110（5）： 1652-1657.
[12]	KOUL A， DEO S， BOOY E P， et al. Impact of double-stranded RNA characteristics on the activation of human 2'-5'-oligoadenylate synthetase 2 （OAS2）［J］. Biochem Cell Biol， 2020， 98（1）： 70-82.
[13]	KRISTIANSEN H， GAD H H， ESKILDSEN-LARSEN S， et al. The oligoadenylate synthetase family： an ancient protein family with multiple antiviral activities［J］. J Interferon Cytokine Res， 2011， 31（1）： 41-47.
[14]	SILVERMAN R H. A scientific journey through the 2-5A/RNase L system［J］. Cytokine Growth Factor Rev， 2007， 18（5/6）： 381-388.
[15]	ZHAO M M， WAN B， LI H W， et al. Porcine 2'，5'- oligoadenylate synthetase 2 inhibits porcine reproductive and respiratory syndrome virus replication in vitro ［J］. Microb Pathog， 2017， 111： 14-21.
[16]	LOPP A， REINTAMM T， KUUSKSALU A， et al. Natural occurrence of 2'，5'-linked heteronucleotides in marine sponges［J］. Mar Drugs， 2010， 8（2）： 235-254.
[17]	RUSCH L， ZHOU A M， SILVERMAN R H. Caspase-dependent apoptosis by 2'，5'-oligoadenylate activation of RNase L is enhanced by IFN-β［J］. J Interf Cytokine Res， 2000， 20（12）： 1091-1100.
[18]	ZHOU A M， PARANJAPE J， BROWN T L， et al. Interferon action and apoptosis are defective in mice devoid of 2'， 5'-oligoadenylate‐dependent RNase L［J］. EMBO J， 1997， 16（21）： 6355-6363.
[19]	CHAWLA-SARKAR M， LINDNER D J， LIU Y F， et al. Apoptosis and interferons： Role of interferon-stimulated genes as mediators of apoptosis［J］. Apoptosis， 2003， 8（3）： 237-249.
[20]	CHAKRABARTI A， JHA B K， SILVERMAN R H. New insights into the role of RNase L in innate immunity［J］. J Interferon Cytokine Res， 2011， 31（1）： 49-57.
[21]	BANDAY A R， STANIFER M L， FLOREZ-VARGAS O， et al. Genetic regulation of OAS1 nonsense-mediated decay underlies association with COVID-19 hospitalization in patients of European and African ancestries［J］. Nat Genet， 2022， 54（8）： 1103-1116.
[22]	SCHMIEDEL B J， ROCHA J， GONZALEZ-COLIN C， et al. COVID-19 genetic risk variants are associated with expression of multiple genes in diverse immune cell types［J］. Nat Commun， 2021， 12： 6760.
[23]	LÓPEZ-RODRÍGUEZ R， HERNÁNDEZ-BARTOLOMÉ Á， BORQUE M J， et al. Interferon-related genetic markers of necroinflammatory activity in chronic hepatitis C［J］. PLoS One， 2017， 12（7）： e0180927.
[24]	BARKHASH A V， PERELYGIN A A， BABENKO V N， et al. Variability in the 2'-5'-oligoadenylate synthetase gene cluster is associated with human predisposition to tick-borne encephalitis virus： induced disease［J］. J Infect Dis， 2010， 202（12）： 1813-1818.
[25]	TAN Y X， WANG H， LV H， et al. Polymorphism of OAS2 rs739901 C/A involves the susceptibility to EV71 infection in Chinese children［J］. Curr Med Sci， 2018， 38（4）： 640-647.
[26]	WANG S S， GONZALEZ P， YU K， et al. Common genetic variants and risk for HPV persistence and progression to cervical cancer［J］. PLoS One， 2010， 5（1）： e8667.
[27]	SU X W， YEE L J， IM K， et al. Association of single nucleotide polymorphisms in interferon signaling pathway genes and interferon-stimulated genes with the response to interferon therapy for chronic hepatitis C［J］. J Hepatol， 2008， 49（2）： 184-191.
[28]	YAKUB I， LILLIBRIDGE K M， MORAN A N， et al. Single nucleotide polymorphisms in genes for 2'-5'- oligoadenylate synthetase and RNase L in patients hospitalized with west Nile virus infection［J］. J Infect Dis， 2005， 192（10）： 1741-1748.
[29]	GAO L J， REN R M， SHEN J， et al. Values of OAS gene family in the expression signature， immune cell infiltration and prognosis of human bladder cancer［J］. BMC Cancer， 2022， 22（1）： 1016.
[30]	MANDAL S， ABEBE F， CHAUDHARY J. 2'-5' oligoadenylate synthetase 1 polymorphism is associated with prostate cancer［J］. Cancer， 2011， 117（24）： 5509-5518.
[31]	BHOSLE S M， HUNT A， CHAUDHARY J. A modified coupled spectrophotometric method to detect 2-5 oligoadenylate synthetase activity in prostate cell lines［J］. Biol Proced Online， 2016， 18（1）： 9.
[32]	YAN S B， FANG J T， ZHU Y Q， et al. Comprehensive analysis of prognostic immune-related genes associated with the tumor microenvironment of pancreatic ductal adenocarcinoma［J］. Oncol Lett， 2020， 20（6）： 366.
[33]	WEN X， SHAO Z Y， CHEN S Y， et al. Construction of an RNA-binding protein-related prognostic model for pancreatic adenocarcinoma based on TCGA and GTEx databases［J］. Front Genet， 2021， 11： 610350.
[34]	CHE L， YANG H R， WANG D J， et al. Corylin sensitizes breast cancer cells to overcome tamoxifen resistance by regulating OAS1/miR-22-3p/SIRT1 axis［J］. Acta Biochim Pol， 2021， 68（4）： 757-764.
[35]	MOTAGHED M， AL-HASSAN F M， HAMID S S. Thymoquinone regulates gene expression levels in the estrogen metabolic and interferon pathways in MCF7 breast cancer cells［J］. Int J Mol Med， 2014， 33（1）： 8-16.
[36]	ZHANG M， LV X T， JIANG Y J， et al. Identification of aberrantly methylated differentially expressed genes in glioblastoma multiforme and their association with patient survival［J］. Exp Ther Med， 2019， 18（3）： 2140-2152.
[37]	HSU Y B， HUANG C F， LIN K T， et al. Podoplanin， a potential therapeutic target for nasopharyngeal carcinoma［J］. BioMed Res Int， 2019， 2019： 7457013.
[38]	CHEN F X， WANG Q Q， ZHOU Y F. The construction and validation of an RNA binding protein-related prognostic model for bladder cancer［J］. BMC Cancer， 2021， 21（1）： 244.
[39]	NOGUCHI S， YAMADA N， KUMAZAKI M， et al. socs7， a target gene of microRNA-145， regulates interferon-β induction through STAT3 nuclear translocation in bladder cancer cells［J］. Cell Death Dis， 2013， 4（2）： e482.
[40]	DOMINGO-GIL E， ESTEBAN M. Role of mitochondria in apoptosis induced by the 2-5A system and mechanisms involved［J］. Apoptosis， 2006， 11（5）： 725-738.
[41]	MELCHJORSEN J， KRISTIANSEN H， CHRISTIANSEN R， et al. Differential regulation of the OASL and OAS1 genes in response to viral infections［J］. J Interf Cytokine Res， 2009， 29（4）： 199-208.
[42]	SHINDO M， HAMADA K， MORIKAWA T， et al. In vivo interferon system assessed by 2'-5' oligoadenylate synthetase activity in chronic hepatitis C virus patients treated with pegylated interferon and ribavirin［J］. Hepatol Res， 2008， 38（12）： 1213-1220.
[43]	DAR A A， PRADHAN T N， KULKARNI D P， et al. Extracellular 2'5'-oligoadenylate synthetase 2 mediates T-cell receptor CD3-ζ chain down-regulation via caspase-3 activation in oral cancer［J］. Immunology， 2016， 147（2）： 251-264.
[44]	KIM J C， HA Y J， TAK K H， et al. Opposite functions of GSN and OAS2 on colorectal cancer metastasis， mediating perineural and lymphovascular invasion， respectively［J］. PLoS One， 2018， 13（8）： e0202856.
[45]	KIM C W， HA Y J， TAK K H， et al. Clinically applicable serum biomarkers among 14 candidates associated with recurrence of stage Ⅱ and Ⅲ colorectal cancer［J］. Anticancer Res， 2021， 41（9）： 4651-4658.
[46]	WANG Q Q， CHEN P Z， WANG X R， et al. piR-36249 and DHX36 together inhibit testicular cancer cells progression by upregulating OAS2［J］. Non Coding RNA Res， 2023， 8（2）： 174-186.
[47]	ZHANG Y J， YU C R. Prognostic characterization of OAS1/OAS2/OAS3/OASL in breast cancer［J］. BMC Cancer， 2020， 20（1）： 575.
[48]	HO W J， LAW A M K， MASLE-FARQUHAR E， et al. Activation of the viral sensor oligoadenylate synthetase 2 （Oas2） prevents pregnancy-driven mammary cancer metastases［J］. Breast Cancer Res， 2022， 24（1）： 31.
[49]	DOHERTY M R， CHEON H， JUNK D J， et al. Interferon-beta represses cancer stem cell properties in triple-negative breast cancer［J］. Proc Natl Acad Sci U S A， 2017， 114（52）： 13792-13797.
[50]	LI X Y， HOU L， ZHANG L Y， et al. OAS3 is a co-immune biomarker associated with tumour microenvironment， disease staging， prognosis， and treatment response in multiple cancer types［J］. Front Cell Dev Biol， 2022， 10： 815480.
[51]	YOU Q S， SHEN H. Development of multivariable risk signature based on four immune-related RNA-binding proteins to predict survival and immune status in lung adenocarcinoma［J］. Transl Cancer Res TCR， 2022， 11（8）： 2591-2606.
[52]	SHI Y L， XU Y， XU Z Y， et al. TKI resistant-based prognostic immune related gene signature in LUAD in which FSCN1 contributes to tumor progression［J］. Cancer Lett， 2022， 532： 215583.
[53]	CASARRUBIOS M， PROVENCIO M， NADAL E， et al. Tumor microenvironment gene expression profiles associated to complete pathological response and disease progression in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy［J］. J Immunother Cancer， 2022， 10（9）： e005320.
[54]	YU C R， XUE P， ZHANG L Y， et al. Prediction of key genes and pathways involved in trastuzumab-resistant gastric cancer［J］. World J Surg Oncol， 2018， 16（1）： 174.
[55]	ALAM M S， SULTANA A， REZA M S， et al. Integrated bioinformatics and statistical approaches to explore molecular biomarkers for breast cancer diagnosis， prognosis and therapies［J］. PLoS One， 2022， 17（5）： e0268967.
[56]	YAN L， HU C Y， JI Y Y， et al. Identification of significant secreted or membrane-located proteins in laryngeal squamous cell carcinoma［J］. J Immunol Res， 2022， 2022： 9089397.
[57]	TANG D， WU Q， YUAN Z， et al. Identification of key pathways and genes changes in pancreatic cancer cells （BXPC-3） after cross-talk with primary pancreatic stellate cells using bioinformatics analysis［J］. Neoplasma， 2019， 66（5）： 681-693.
[58]	DENG L H， GU X P， ZENG T， et al. Identification and characterization of biomarkers and their functions for docetaxel-resistant prostate cancer cells［J］. Oncol Lett， 2019， 18（3）：3236-3248.
[59]	TSAI M H， COOK J A， CHANDRAMOULI G V R， et al. Gene expression profiling of breast， prostate， and glioma cells following single versus fractionated doses of radiation［J］. Cancer Res， 2007， 67（8）： 3845-3852.
[60]	SIM C K， CHO Y S， KIM B S， et al. 2'-5' Oligoadenylate synthetase-like 1 （OASL1） deficiency in mice promotes an effective anti-tumor immune response by enhancing the production of type Ⅰ interferons［J］. Cancer Immunol Immunother， 2016， 65（6）： 663-675.
[61]	SIM C K， LEE J H， BAEK I J， et al. Enhanced antitumor immune response in 2'-5' oligoadenylate synthetase-like 1- （OASL1-） deficient mice upon cisplatin chemotherapy and radiotherapy［J］. J Immunol Res， 2019， 2019： 7596786.
[62]	LV J P， WANG L Y， SHEN H， et al. Regulatory roles of OASL in lung cancer cell sensitivity to Actinidia chinensis Planch root extract （acRoots）［J］. Cell Biol Toxicol， 2018， 34（3）： 207-218.
[63]	ZHAO W Z， YANG H Y， LIU L G， et al. OASL knockdown inhibits the progression of stomach adenocarcinoma by regulating the mTORC1 signaling pathway［J］. FASEB J， 2023， 37（3）： e22824.
[64]	CHEN S H， SUN Z J， ZHAO W Z， et al. Oligoadenylate synthetases-like is a prognostic biomarker and therapeutic target in pancreatic ductal adenocarcinoma［J］. Ann Transl Med， 2022， 10（3）： 138.
[65]	GLAß M， MICHL P， HÜTTELMAIER S. RNA binding proteins as drivers and therapeutic target candidates in pancreatic ductal adenocarcinoma［J］. Int J Mol Sci， 2020， 21（11）： 4190.
[66]	WALDMANN T A. Cytokines in cancer immunotherapy［J］. Cold Spring Harb Perspect Biol， 2018， 10（12）： a028472.
[67]	SISSOLAK G， HOFFBRAND A V， MEHTA A B， et al. Interferon-alpha inducible 2'-5' oligoadenylate synthetase transcripts in lymphoid and myeloid leukemias［J］. Leukemia， 1993， 7（5）： 712-716.
[68]	ZHOU H， JIA X F， YANG F， et al. Long noncoding RNA SATB1-AS1 contributes to the chemotherapy resistance through the microRNA-580/2'-5'- oligoadenylate synthetase 2 axis in acute myeloid leukemia［J］. Bioengineered， 2021， 12（1）： 6403-6417.
[69]	SAVA G P， SPEEDY H E， DI BERNARDO M C， et al. Common variation at 12q24.13 （OAS3） influences chronic lymphocytic leukemia risk［J］. Leukemia， 2015， 29（3）： 748-751.

Research progress on functions of oligoadenylate synthetase gene family and their roles in occurrence and development of tumor

RichHTML

PDF (PC)

Like

Knowledge

Abstract

Cite this article

share this article

References 69

Related Articles 15

Metrics

Comments

Recommended 0

[1]	Jiaxin LI,Xiongbing HU,Juan LI. Effect of co-expression of B2M protein on biological behaviors of third-generation CAR-T cells targeting mesothelin [J]. Journal of Jilin University(Medicine Edition), 2026, 52(5): 1224-1233.
[2]	Junming LIU,Jingting LI,Nan LIANG,Wanning ZHANG,Yantao FU. Primary thyroid clear cell sarcoma of soft tissue with EWSR1 gene rearrangement: A case report and literature review [J]. Journal of Jilin University(Medicine Edition), 2026, 52(5): 1460-1466.
[3]	Yuan GAO,Wenying GAO,Wenyan ZHANG. Research progress in interaction of glycosylation and ubiquitination modifications in disease occurrence and development and viral infection [J]. Journal of Jilin University(Medicine Edition), 2026, 52(5): 1483-1490.
[4]	Laiping LI,Guifeng LI,Ruijing DU,Jinzhi PENG,Peixue YAO,Huan JIN. Research progress in biological roles of m⁶A reader protein IGF2BP3 in development and progression of malignant tumor [J]. Journal of Jilin University(Medicine Edition), 2026, 52(5): 1491-1502.
[5]	Mian QIN,Li YAN,Lu BAI,Shengnan JIA,Xiuyan YU. Research progress in role of lncRNA-mediated ceRNA regulation in development and progression of pancreatic cancer [J]. Journal of Jilin University(Medicine Edition), 2026, 52(5): 1512-1519.
[6]	Rui LI,Xiaoyan HAO,Liu YANG,Jiayun LIU,Mu HE. Construction and validation of machine learning-based prediction models for esophageal cancer using routine clinical laboratory data [J]. Journal of Jilin University(Medicine Edition), 2026, 52(4): 1086-1095.
[7]	Pingxu AN,Qi HUANG,Xinyu HONG. Research progress in immunotherapy and anti-angiogenic therapy under pituitary adenoma tumor microenvironment [J]. Journal of Jilin University(Medicine Edition), 2026, 52(4): 1170-1178.
[8]	Qian AO,Nan LIANG,Hui SUN. Research progress in regulation of tumor-related signaling pathways by acetylation modification and its potential applications in tumor therapy [J]. Journal of Jilin University(Medicine Edition), 2026, 52(4): 1179-1186.
[9]	Jiaxin LI,Xinyang ZHANG. Bioinformatics analysis on effect of chemokine receptor 6 expression on tumor immune microenvironment and its impact on regulatory T lymphocyte function [J]. Journal of Jilin University(Medicine Edition), 2026, 52(4): 881-892.
[10]	Jiangfen LI,Xinzhi FANG. Promotion effect of exosome-regulated macrophage polarization on proliferation and metastasis of human esophageal squamous cell carcinoma cells and its mechanism [J]. Journal of Jilin University(Medicine Edition), 2026, 52(4): 987-998.
[11]	Gengfei CAO, SHAYA·Mahati,Junpeng GU,Weizheng JI, ASIHAER·Hasimu,Weixin REN. Differences in immune microenvironment between DEB-TACE and c-TACE in treatment of hepatocellular carcinoma and mechanism of TRADD-mediated Th17 differentiation [J]. Journal of Jilin University(Medicine Edition), 2026, 52(3): 764-780.
[12]	Zhipeng PAN,Le WANG,Weiwen HUANG,Zhen YI,Yuxuan GAO. Bioinformatics analysis and experimental validation based on screening and identification of diagnostic candidate genes of bone marrow mononuclear cells of acute myeloid leukemia patients and their impact on prognosis [J]. Journal of Jilin University(Medicine Edition), 2026, 52(3): 791-805.
[13]	Changfeng LIU,Guangjun JIN,Yonggang WANG. Primary renal angiosarcoma with multiple abdominal haemorrhages： A case repert and literature review [J]. Journal of Jilin University(Medicine Edition), 2026, 52(3): 821-827.
[14]	Qiuping SU,Lei XING,Wei ZHANG,Shan JIANG,Yangyang ZHAO,Fangfang CHEN. Research progress in anti-tumor mechanism of berberine and application of its novel nano-delivery system in tumor therapy [J]. Journal of Jilin University(Medicine Edition), 2026, 52(3): 863-871.
[15]	Yang YU,Sheyu YE,Kexin WEI,Zhicheng WANG. Research progress in formation mechanism of tumor radioresistance and inhibitory effect of low-dose radiotherapy combination with novel sensitization strategies on tumor radioresistance [J]. Journal of Jilin University(Medicine Edition), 2026, 52(3): 872-880.